Oncology (all articles)
Review | Patient-centered care in the management of cancer during pregnancy
6 Jun, 2023 | 14:10h | UTCPatient-Centered Care in the Management of Cancer During Pregnancy – ASCO Educational Book
See other articles in the series: 2023 ASCO Educational Book
RCT | Noninferiority shown between DOACs and LMWH for recurrent VTE prevention in cancer patients
5 Jun, 2023 | 13:50h | UTCSummary: This unblinded, pragmatic, noninferiority randomized clinical trial aimed to assess the efficacy of direct oral anticoagulants (DOACs) against low-molecular-weight heparin (LMWH) in preventing recurrent venous thromboembolism (VTE) in patients with cancer. The study included 671 patients from 67 oncology centers, with a new clinical or radiological diagnosis of VTE.
Participants were randomly assigned to receive either a DOAC or LMWH for 6 months, and treating physicians selected and prescribed the drugs based on considerations like availability and drug-drug interactions. The primary outcome was the rate of recurrent VTE at 6 months. Findings revealed that the DOAC group had a recurrent VTE rate of 6.1% as compared to 8.8% in the LMWH group, showing noninferiority. Both groups had statistically similar rates of major bleeding and severe adverse events.
This pragmatic study included patients with advanced cancer and brain metastases, impaired performance status, and reduced liver or kidney function, making it more representative of routine oncology practice. Moreover, patient adherence to DOAC treatment was significantly higher than to LMWH. Nevertheless, the study had limitations, including the lack of blinding and underrepresentation of certain racial and ethnic groups.
In conclusion, this trial suggests that DOACs were noninferior to LMWH for preventing recurrent VTE in patients with cancer over a 6-month follow-up period, supporting the use of DOACs in this population for VTE prevention. Further research is needed to confirm these results and investigate long-term outcomes.
Article: Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual abstract
Commentary on Twitter
Among adults with cancer and VTE, direct oral anticoagulants were noninferior to low-molecular-weight heparin for preventing recurrent VTE over 6-month follow-up. #ASCO23 https://t.co/DP5RvlSYxe pic.twitter.com/rBJ99plopK
— JAMA (@JAMA_current) June 2, 2023
Review | Prevention of venous thromboembolism in patients with cancer
5 Jun, 2023 | 13:48h | UTCPrevention of venous thromboembolism in patients with cancer – The BMJ
RCT | Osimertinib improves overall survival in resected EGFR-mutated NSCLC, but validity of control group questioned on social media
5 Jun, 2023 | 13:46h | UTCOverall Survival with Osimertinib in Resected EGFR-Mutated NSCLC – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter by Dr. Vinay Prasad (recommended – click to see the video)
Here is the REAL @Plenary_Session on #ADAURA #ASCO23 #ASCO2023
38.5% of people who had recurrence got OSI (very low!)
That just isn't good enough
Brain staging is suboptimal= occult met disease
Would you let your mother be on the control arm and not get OSI on progression? pic.twitter.com/CU3jtrvFOj— Vinay Prasad MD MPH (@VPrasadMDMPH) June 5, 2023
#ASCO23 – RCT | Simple hysterectomy shown non-inferior to radical hysterectomy in low-risk early-stage cervical cancer
5 Jun, 2023 | 13:43h | UTCCommentaries:
Review | Advances in systemic therapies for triple negative breast cancer
5 Jun, 2023 | 13:36h | UTCAdvances in systemic therapies for triple negative breast cancer – The BMJ
Cohort Study | Overweight or obesity in early and middle adulthood linked to higher gastrointestinal cancer risk
5 Jun, 2023 | 13:34h | UTCEditorial: Obesity and Gastrointestinal Cancer: A Life Course Perspective – JAMA Network Open
Commentary: Association Between Overweight/Obesity and Risk of Gastrointestinal Cancer – The ASCO Post
Clinical Trial Update | Olaparib plus bevacizumab first-line maintenance in ovarian cancer
5 Jun, 2023 | 13:07h | UTCOriginal Study: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer – New England Journal of Medicine
The future of cancer care at home: findings from an American Cancer Society summit
31 May, 2023 | 13:48h | UTC
RCT | Microdosed incisional clindamycin reduces infection rate in skin cancer surgery
30 May, 2023 | 12:03h | UTCEffect of Microdoses of Incisional Antibiotics on the Rate of Surgical Site Infections in Skin Cancer Surgery: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
See also: Visual Abstract
Commentary: Microdosed Incisional Clindamycin Cuts SSI After Skin Cancer Surgery – HealthDay
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
30 May, 2023 | 11:51h | UTC
M-A | Prehabilitation may enhance functional capacity in pre- and postoperative colorectal cancer patients
30 May, 2023 | 11:50h | UTCSummary: Preparing a patient with bowel cancer for surgery with multiple interventions – Cochrane Library
Review | Spurious electrolyte and acid-base disorders in the patient with cancer
30 May, 2023 | 11:43h | UTC
Commentary on Twitter
Spurious Electrolyte and Acid-Base Disorders in the Patient With Cancer: A Review https://t.co/i9jPRxBdkz (FREE)
@raad_chowdhury @NephroMD @bdubNephro @PITTRenal pic.twitter.com/FbhovMDHd7
— AJKD (@AJKDonline) May 27, 2023
Review | Managing menopausal symptoms, fertility, and bone health in breast cancer women on endocrine therapy
30 May, 2023 | 11:40h | UTC
Review | Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
29 May, 2023 | 11:08h | UTCMitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Commentary on Twitter
In a Review now published online, @maryam_lustberg @NicoleKuderer @ADesaiMD @crisbergerot and @gary_lyman discuss the mitigation of long-term toxicities from cancer treatment, including financial toxicity and psychosocial needs: https://t.co/Gu08RtT0nO pic.twitter.com/OX9tUZyuY5
— NatureRevClinOncol (@NatRevClinOncol) May 25, 2023
MASCC Guidelines for the prevention and management of acute radiation dermatitis | Part 1 – Systematic review
29 May, 2023 | 10:53h | UTCRelated:
RCT | Bacterial decolonization for prevention of radiation dermatitis
RCT | Mepitel film for the prevention of acute radiation dermatitis in breast cancer.
SR | Management of lymph node–positive penile cancer
24 May, 2023 | 13:03h | UTCManagement of Lymph Node–positive Penile Cancer: A Systematic Review – European Urology
USPSTF Draft Statement recommends biennial screening mammography for women ages 40 to 74 years
22 May, 2023 | 13:56h | UTCBreast Cancer: Screening – U.S. Preventive Services Task Force
Critical perspectives on the statement:
Earlier screening for breast cancer: Benefits and harms – Lown Institute
Why more mammograms aren’t the solution to breast cancer – Vox
Review | Cholangiocarcinoma — novel biological insights and therapeutic strategies
22 May, 2023 | 13:38h | UTC
Commentary on Twitter
In a new Review, Greg Gores & co. discuss advances in cholangiocarcinoma over the past 5 yrs, focusing on the immune TME, CAFs, molecular diagnostics & classifications, target therapy, immunotherapy & transplantation:https://t.co/f4BYxY69tk #hpbcsm #medonc #camoldx #camicroenv pic.twitter.com/lqmwgp9hxh
— NatureRevClinOncol (@NatRevClinOncol) May 16, 2023
ASCO Guideline Update | ESR1 mutation testing for HR+/HER2- metastatic breast cancer therapy
22 May, 2023 | 13:27h | UTC
Epidemiology of bladder cancer in 2023: a systematic review of risk factors
22 May, 2023 | 13:23h | UTCEpidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors – European Urology
Review | Hereditary colorectal, gastric, and pancreatic cancer
18 May, 2023 | 13:43h | UTCHereditary colorectal, gastric, and pancreatic cancer: comprehensive review – BJS Open
Commentary on Twitter
Have a🔎at our latest comprehensive review covering all u need to know📜about hereditary 🧬colorectal, gastric & pancreatic🦀! https://t.co/y1LL0DNRiy@Adductor @DrRABurkhart #SoMe4Surgery #StepUp4CRC #SurgEd #MedTwitter @BJSAcademy @BJSurgery @juliomayol @young_bjs Great read! pic.twitter.com/JmmOmMBydO
— BJS Open (@BjsOpen) May 11, 2023
RCT | Cabozantinib addition to nivolumab and ipilimumab extends progression-free survival in renal-cell carcinoma
18 May, 2023 | 13:38h | UTCCabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Cabozantinib in Renal-Cell Carcinoma – NEJM Resident 360
Commentary on Twitter
Clinical Pearls & Morning Reports: Cabozantinib in Renal-Cell Carcinoma. How did the addition of cabozantinib to nivolumab and ipilimumab affect outcomes in the trial by Choueiri et al.? https://t.co/x1FzWBiasr #MedEd #MedTwitter pic.twitter.com/w4sns1ifLG
— NEJM Resident 360 (@NEJMres360) May 16, 2023
Current perioperative care in pancreatoduodenectomy: a step-by-step surgical roadmap from first visit to discharge
16 May, 2023 | 14:52h | UTC
Commentary on Twitter
Step by step surgical roadmap 🗺️ for pancreatoduodenectomy
🧭 Pre, intra and post operative periods have specific landmarks
⚖️ Such factors weight the actual value of surgery vs. alternative options
🔑 is minimize complications and patients selectionhttps://t.co/3obsQdfHs6 pic.twitter.com/6EHoRjc2wE
— Giovanni Marchegiani (@Gio_Marchegiani) April 27, 2023
Cohort Study | 5-mm margins may be adequate for T1a melanoma excision near critical structures
16 May, 2023 | 14:40h | UTCAssociation of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures – JAMA Dermatology (link to abstract – $ for full-text)
Commentary: Melanoma Excisions with 5 Millimeter Margins Linked to Less Risk of Local Recurrence – HCP Live
Commentary on Twitter
Study on thin melanomas (T1a) near critical anatomic sites such as the head and face showed that 5-mm surgical margins may be safe for patients and decrease reconstructive surgery and potential adverse, including scarring and mental issues. https://t.co/Mw7Ub4xMVX
— JAMA Dermatology (@JAMADerm) April 12, 2023